Pharma company, Global Longlife Hospitals and Research is all set to launch its Initial Public Offering (IPO) on April 21. The IPO will be available till April 25.
under SME IPOThe lot size will be 1000 shares at the price 140 per share.
The issue size is an aggregate of 3,500,000 equity shares 49 crores. 50% is reserved for non-institutional investors while the remaining 50% is earmarked for retail investors.
The net proceeds of the issue will be used for land acquisition on leasehold basis, repayment of existing loans and for general corporate purposes.
After the IPO, the company is expected to be listed on BSE SME.
Ahmedabad based Global Longlife Hospital & Research is a multi-specialty tertiary care hospital providing health care services.
Promoted by Sureshkumar Babulal Jani and Dhruv Sureshkumar Jani, the company is well equipped with 110 beds in medical and surgical specialties. In addition, the company offers services such as oncology, ophthalmology, cardiology, dermatology, gynecology, spine surgery, plastic surgery, ultrasound, microbiology, dialysis and physiotherapy among other health services.
The company is certified by the National Accreditation Board for Hospitals and Healthcare Providers (“NABH Accredited”). The company has a team of 11 full time consultants and more than 30 experienced doctors to serve the patients. Its workforce includes 37 nurses and over 50 paramedical, pharmacist, corporate and support staff.
As of December 31, 2021, the total assets and revenue of the company was 40.01 crore and 26.74 crores respectively. while PAT stands 3.86 crores.
The SME IPO allotment date is scheduled for 29th April 2022 and the shares are being listed on 05th May 2022.